



July 8, 2025

PeptiDream Inc.
<https://www.peptidream.com/>
(TSE Prime Market: 4587)
PDRadiopharma Inc.
<https://www.pdradiopharma.com/>

PeptiDream Announces Submission of IND Application for Clinical Trials of ^{177}Lu -PSMA-I&T and ^{64}Cu -PSMA-I&T

KANAGAWA, JAPAN – July 8, 2025 - PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter "PeptiDream")(Tokyo: 4587) today announced that PDRadiopharma Inc. (President: Masato Murakami, Headquarters: Chuo-ku, Tokyo, Japan, "PDRadiopharma"), a wholly owned subsidiary of PeptiDream, has submitted investigational new drug ("IND") applications to the Pharmaceuticals and Medical Devices Agency ("PMDA") in Japan for the initiation of clinical trials of ^{177}Lu -PSMA-I&T and ^{64}Cu -PSMA-I&T, radiopharmaceuticals targeting prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells.

The two agents ^{177}Lu -PSMA-I&T and ^{64}Cu -PSMA-I&T are jointly developed by Curium (CEO: Renaud Dehareng, Headquarters: Boston, Massachusetts, the United States) and PDRadiopharma for prostate cancer for treatment and diagnostics (theranostic pair) in Japan based on the strategic partnership between two companies.

The clinical trial for ^{177}Lu -PSMA-I&T will evaluate its efficacy and safety in patients with metastatic castration-resistant prostate cancer (mCRPC). The trial for ^{64}Cu -PSMA-I&T will evaluate its diagnostic performance using PET/CT in patients with newly diagnosed prostate cancer. Both trials aim to leverage data from Curium's ongoing global studies to expedite regulatory approval in Japan.

About ^{177}Lu -PSMA-I&T and ^{64}Cu -PSMA-I&T

Curium is conducting clinical trials for ^{177}Lu -PSMA-I&T and ^{64}Cu -PSMA-I&T. For ^{177}Lu -PSMA-I&T, a global Phase 3 pivotal trial (ECLIPSE trial, ClinicalTrials.gov identifier; NCT05204927) targeting patients with metastatic castration-resistant prostate cancer (mCRPC) has been conducted, and it has been reported that the primary endpoint was met, demonstrating a statistically significant and clinically meaningful benefit for patients with PSMA-positive mCRPC. For ^{64}Cu -PSMA-I&T, trials are being conducted to diagnose biochemical recurrence of prostate cancer (SOLAR RECUR trial, ClinicalTrials.gov identifier NCT06235099) and for men newly diagnosed with unfavorable intermediate to very high-risk prostate cancer, electing to undergo surgery (SOLAR STAGE trial, ClinicalTrials.gov identifier; NCT06235151).

About Prostate Cancer

Prostate cancer continues to be widely prevalent in Japan. Annually, there are approximately 90,000 – 100,000 new cases, with patients with metastatic castration resistant prostate cancer having an overall survival rate of approximately three years in clinical trial settings, and even

shorter in the real-world, and there remains a significant unmet medical need for therapies.

About PeptiDream Inc.

PeptiDream Inc. (Tokyo Stock Exchange Prime Section 4587) is leading the translation of macrocyclic peptides into a whole new class of innovative medicines to address unmet medical needs and improve the quality of life of patients worldwide. In its radiopharmaceutical business, through its wholly-owned subsidiary PDRadiopharma, PeptiDream markets and sells a number of approved radiopharmaceuticals and radiodiagnostics in Japan, as well as leveraging its proprietary Peptide Discovery Platform System (PDPS) technology to discover and develop a deep pipeline of innovative targeted radiotherapeutics and radiodiagnostics, spanning both wholly-owned internal programs and globally partnered programs. In its non-radiopharmaceutical business, PeptiDream is similarly leveraging PDPS to discover and develop a broad and diverse pipeline of investigational peptide therapeutics, peptide drug conjugates (PDC) and multi-functional peptide conjugates (MPC) across an extensive global network of discovery and development partners. PeptiDream is headquartered in Kawasaki, Japan. For more information about our company, science and pipeline, please visit www.peptidream.com/en/

About PDRadiopharma

PDRadiopharma, a wholly-owned subsidiary of PeptiDream from 2022, has been providing high-quality radiopharmaceuticals through the research and development, manufacturing, regulatory and sales as a forerunner in the field in radiopharmaceuticals, since it started its business in 1968. PDRadiopharma currently markets 22 radiodiagnostic products (spanning both SPECT and PET products) and 8 radiotherapeutic products (3 product categories) in Japan. Additionally, PDRadiopharma and PeptiDream are developing a broad pipeline of radiotherapeutics and radiodiagnostics for both the Japan and global markets. For more information about PDRadiopharma, please visit www.pdradiopharma.com/en

Inquiries:

PeptiDream Inc.

Contact: Yuko Okimoto, IR & Public Affairs

Email: info@peptidream.com

Website: <https://www.peptidream.com/en/>

X: <https://x.com/PeptidreamInc>

PDRadiopharma Inc.

Contact: Noriko Tanaka, General Affairs

Email: s-info-hq@pdradiopharma.com